Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

Recently, two studies using ipilimumab, an anti-CTLA-4 monoclonal antibody (mab) demonstrated improvements in overall survival in the treatment of advanced melanoma. These studies utilized two different schedules of treatment in different patient categories (first and second line of treatment). Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ascierto, Paolo A, Marincola, Francesco M, Ribas, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262765/
https://www.ncbi.nlm.nih.gov/pubmed/22077981
http://dx.doi.org/10.1186/1479-5876-9-196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262765/
https://www.ncbi.nlm.nih.gov/pubmed/22077981
http://dx.doi.org/10.1186/1479-5876-9-196

Ejemplares similares